[Comparison of RePUVA and aromatic retinoid Ro 10-9359 with methotrexate in severe forms of psoriasis].
Treatment of 20 PUVA-resistant patients with aromatic retinoid Ro 10-9359 resulted in a considerable improvement of psoriasis up to total recovery, and potentiated a favorable clinical effect of subsequent PUVA-treatment with reduced 8-MOP dosage. Aromatic retinoid was especially effective in patients with psoriatic eruptions on palms, soles, face, and scalp. The combination of aromatic retinoid with methotrexate was successfully used in the treatment of two patients with a particularly severe course of psoriasis, one having psoriatic erythroderma coupled with psoriatic arthritis and the other psoriatic erythroderma. No side-effects were noted during retinoid treatment in any of the patients examined.
D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005050:Etretinate / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D008730:Methoxsalen / Q000627:therapeutic use; D011701:PUVA Therapy / Q000379:methods*; D010778:Photochemotherapy / Q000379:methods*; D011565:Psoriasis / Q000188:drug therapy*; D014212:Tretinoin / Q000031:analogs & derivatives*
D014212:Tretinoin; D005050:Etretinate; D008730:Methoxsalen; D008727:Methotrexate
Vergleich von RePUVA und aromatischem Retinoid Ro 10-9359 mit Methotrexat bei schweren Psoriasisformen.